<DOC>
	<DOCNO>NCT01632878</DOCNO>
	<brief_summary>The OPTIMISE study prospective , multi-center , multi-national , structure data collection initiative , first compile data current treatment post myocardial infarction patient ( screening-log ) , prospectively evaluate patient prescribe Omacor part standard secondary prevention treatment . The aim observe Omacor cohort patient period 12 month , collect long term observational data clinical patient-reported outcome , especially , exclusively , recurrent non fatal Myocardial Infarction ( MI ) , sudden death , new Congestive Heart Failure ( CHF ) . No predefined additional visit , medical test , lab , procedure intervention mandate . Only result routinely performed test , lab , procedure and/or intervention collect available .</brief_summary>
	<brief_title>Omacor Plus Standard Therapies In Post Myocardial Infarction ( MI ) Subjects Evaluation : The OPTIMISE Observational Study</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Inclusion Criteria Male female patient , screeninglog , prescribe prior inclusion study Omega3fattyacid ethyl ester ( Omacor ) adjuvant treatment secondary prevention myocardial infarction , addition standard therapy [ e.g . statin , antiplatelet medicinal product , beta blocker , Angiotensine Converting Enzyme ( ACE ) inhibitors/Angiotensine II Receptor Blockers ( ARBs ) , etc ] . Exclusion Criteria Omega3fattyacid ethyl ester ( Omacor ) approve contraindication per label information participate country</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Secondary prevention post MI</keyword>
</DOC>